{"doi":"10.2967/jnumed.120.245084","title":"FAPI-74 PET/CT Using Either<sup>18</sup>F-AlF or Cold-Kit<sup>68</sup>Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients","abstract":"<sup>68</sup>Ga-fibroblast activation protein inhibitors (FAPIs) 2, 4, and 46 have already been proposed as promising PET tracers. However, the short half-life of <sup>68</sup>Ga (68 min) creates problems with manufacture and delivery. <sup>18</sup>F (half-life, 110 min) labeling would result in a more practical large-scale production, and a cold-kit formulation would improve the spontaneous availability. The NOTA chelator ligand FAPI-74 can be labeled with both <sup>18</sup>F-AlF and <sup>68</sup>Ga. Here, we describe the in vivo evaluation of <sup>18</sup>F-FAPI-74 and a proof of mechanism for <sup>68</sup>Ga-FAPI-74 labeled at ambient temperature. <b>Methods:</b> In 10 patients with lung cancer, PET scans were acquired at 10 min, 1 h, and 3 h after administration of 259 ± 26 MBq of <sup>18</sup>F-FAPI-74. Physiologic biodistribution and tumor uptake were semiquantitatively evaluated on the basis of SUV at each time point. Absorbed doses were evaluated using OLINDA/EXM, version 1.1, and QDOSE dosimetry software with the dose calculator IDAC-Dose, version 2.1. Identical methods were used to evaluate one examination after injection of 263 MBq of <sup>68</sup>Ga-FAPI-74. <b>Results:</b> The highest contrast was achieved in primary tumors, lymph nodes, and distant metastases at 1 h after injection, with an SUV<sub>max</sub> of more than 10. The effective dose per a 100-MBq administered activity of <sup>18</sup>F-FAPI-74 was 1.4 ± 0.2 mSv, and for <sup>68</sup>Ga-FAPI-74 it was 1.6 mSv. Thus, the radiation burden of a diagnostic <sup>18</sup>F-FAPI-74 PET scan is even lower than that of PET scans with <sup>18</sup>F-FDG and other <sup>18</sup>F tracers; <sup>68</sup>Ga-FAPI-74 is comparable to other <sup>68</sup>Ga ligands. FAPI PET/CT supported target volume definition for guiding radiotherapy. <b>Conclusion:</b> The high contrast and low radiation burden of FAPI-74 PET/CT favor multiple clinical applications. Centralized large-scale production of <sup>18</sup>F-FAPI-74 or decentralized cold-kit labeling of <sup>68</sup>Ga-FAPI-74 allows flexible routine use.","journal":"Journal of Nuclear Medicine","year":2020,"id":49020,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":307,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9556,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":235079,"name":"Sebastian Adeberg","orcid":"0000-0001-8463-514X","position":1,"is_corresponding":false},{"id":235080,"name":"Mustafa Syed","orcid":"0000-0002-7841-7792","position":2,"is_corresponding":false},{"id":235081,"name":"Thomas Lindner","orcid":"0000-0003-0290-484X","position":3,"is_corresponding":false},{"id":235082,"name":"Luis David Jiménez‐Franco","orcid":"0000-0002-3458-7976","position":4,"is_corresponding":false},{"id":238591,"name":"Eleni Mavriopoulou","orcid":null,"position":5,"is_corresponding":false},{"id":238592,"name":"Fabian Staudinger","orcid":null,"position":6,"is_corresponding":false},{"id":238593,"name":"Eric Tonndorf‐Martini","orcid":null,"position":7,"is_corresponding":false},{"id":235083,"name":"Sebastian Regnery","orcid":"0000-0002-6820-884X","position":8,"is_corresponding":false},{"id":238594,"name":"Stefan Rieken","orcid":null,"position":9,"is_corresponding":false},{"id":235084,"name":"Rami A. El Shafie","orcid":"0000-0002-1355-7882","position":10,"is_corresponding":false},{"id":235085,"name":"Manuel Röhrich","orcid":"0000-0001-7609-243X","position":11,"is_corresponding":false},{"id":238595,"name":"Paul Flechsig","orcid":null,"position":12,"is_corresponding":false},{"id":235086,"name":"Andreas Kluge","orcid":"0009-0008-3761-3958","position":13,"is_corresponding":false},{"id":238596,"name":"Annette Altmann","orcid":null,"position":14,"is_corresponding":false},{"id":235087,"name":"Jürgen Debus","orcid":"0000-0002-6411-4811","position":15,"is_corresponding":false},{"id":235088,"name":"Uwe Haberkorn","orcid":"0000-0001-6630-0338","position":16,"is_corresponding":false},{"id":235089,"name":"Clemens Kratochwil","orcid":"0000-0003-1334-8260","position":17,"is_corresponding":false},{"id":235078,"name":"Frederik L. Giesel","orcid":"0000-0002-9669-5593","position":0,"is_corresponding":true}],"reference_count":56,"raw_metadata":null,"created_at":"2026-07-18T20:36:25.163232Z","pmid":"32591493","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}